A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 2
- 主要终点
- Maximum Tolerated Dose
研究概览
简要总结
LDE225 is a new medicine that blocks the Hedgehog (Hh) pathway. The Hh pathway is a cascade of molecular events that control cell growth and have been linked with the development of many human cancers, including pancreatic cancer. Information from research studies suggests that LDE225 in combination with FOLFIRINOX may help to stop the growth of cancer cells. In this research study, the investigators are looking to determine the maximum dose of LDE225 in combination that can be given safely to patients with locally advanced or metastatic pancreatic cancer.
详细描述
Study medication will be given in cycles of 14 days. Subjects will keep a study drug diary for each treatment cycle. LDE225 capsules will be taken by mouth in the morning every day of each cycle.
On days 1-2 of each cycle, subjects will take LDE225 at the clinic followed by FOLFIRINOX intravenous infusion (through a vein).
Subjects will come to the clinic weekly for the first 5 weeks, then every other week (Week 7, 9, 11, etc.) and receive the following procedures:
Review of current medications and any side effects Physical exam Performance Status Blood tests (2 teaspoons of blood) Assessment of tumor (repeated every 8 weeks) ECG at week 3 and 5
Subjects will also have pharmacokinetic (PK) blood samples taken. PK samples are used to find out the amount of study medication in the blood. Each PK sample is about 1/2 teaspoon of blood. Subjects will have PK samples taken on:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 72 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma
- •Previously untreated locally advanced or metastatic pancreatic adenocarcinoma. Pts newly diagnosed with metastatic recurrence after adjuvant therapy for resected disease are eligible, if completion of adjuvant therapy was > 8 months ago
- •Measurable disease
- •Adequate organ and marrow function
- •Able to take oral drugs
排除标准
- •Concurrent active primary or metastatic cancer other than superficial squamous cell or basal cell skin cancer
- •Pregnant or breastfeeding
- •Receiving any other standard or investigation anticancer agents, with the exception of hormonal therapy
- •Prior chemoradiation to the primary pancreatic tumor unless there is a measurable distant site of disease
- •Known CNS metastases
- •History of hypersensitivity reactions to any components of the treatment regimen
- •Known malabsorption syndromes
- •Neuromuscular disorders
- •Receiving other anti-neoplastic therapy concurrently
- •Requires warfarin/Coumadin for therapeutic coagulation
- •Receiving treatment with medications known to be moderate and strong inhibitors or inducers of CYP3A4/5
- •Uncontrolled diarrhea
- •Peripheral neuropathy > grade 1 due to any cause
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements
- •HIV positive
研究组 & 干预措施
LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
干预措施: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan (Drug)
结局指标
主要结局
Maximum Tolerated Dose
时间窗: 2 years
To determine the maximal tolerated doses of LDE225 in combination with FOLFIRINOX in patients with locally advanced or metastatic pancreatic adenocarcinoma
Toxicity
时间窗: 2 years
To determine the types, frequency, and severity of adverse events occurring in subjects receiving LDE225 in combination with FOLFIRINOX
次要结局
- Response Rate(2 years)
研究者
Jeffrey W. Clark, MD
Physician Hematology/Oncology
Massachusetts General Hospital